Chemoradiotherapy with FOLFOX plus cetuximab in locally advanced oesophageal cancer: The GERCOR phase II trial ERaFOX

网站地图 | English | 公务邮箱

About the library

Background
History
Leadership
Organization

Opening Hours
Collections
Help Via Email

Electronic Information Resources

Chemoradiotherapy with FOLFOX plus cetuximab in locally advanced oesophageal cancer: The GERCOR phase II trial ERaFOX

详细信息查看全文

作者：Gé ; rard Lledo^a ; ^b ; ^{lledogerard@aol.com" class="auth_mail" title="E-mail the corresponding author} ; Florence Huguet^b ; ^c ; Benoist Chibaudel^b ; ^d ; Fré ; dé ; ric Di Fiore^e ; Laurent Mineur^f ; Marie-Pierre Galais^g ; Pascal Artru^a ; Valé ; rie Blondin^e ; Olivier Dupuis^h ; Menouar Samir Abdicheⁱ ; Nicolas Jovenin^j ; Astrid Pozet^k ; Franck Bonnetain^k ; Mohamed Attia^b ; Laetitia Dahan^l ; Aimery de Gramont^b ; ^d
关键词：Oesophageal cancer ; Oxaliplatin ; Radiotherapy ; Chemoradiotherapy ; FOLFOX ; Cetuximab
刊名：European Journal of Cancer
出版年：2016
出版时间：March 2016
年：2016
卷：56
期：Complete
页码：115-121
全文大小：425 K

文摘

•: Radiation therapy with oxaliplatin, 5-fluorouracil, and folinic acid (FOLFOX) and cetuximab provides a 77% clinical response rate.
•: Chemoradiotherapy with concurrent FOLFOX and cetuximab was well tolerated.
•: A high Atkinson's score of dysphagia correlated with poorer survival.

NGLC 2004-2010.National Geological Library of China All Rights Reserved.
Add:29 Xueyuan Rd,Haidian District,Beijing,PRC. Mail Add: 8324 mailbox 100083
For exchange or info please contact us via email.